Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Fluicell AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr13.95 Mil.
Fluicell AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fluicell AB EV-to-EBIT Related Terms
Fluicell AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Fluicell AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:FLUI vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Fluicell AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fluicell AB's EV-to-EBIT falls into.
Fluicell AB's current Enterprise Value is kr20.21 Mil.
Fluicell AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fluicell AB (OSTO:FLUI) has a EV-to-EBIT of -9.27 as of Aug. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #999999 out of 387 companies in the Biotechnology industry.
Is Fluicell AB's EV-to-EBIT too high?
Fluicell AB's current EV-to-EBIT is -9.27. Based on the distribution chart, Fluicell AB ranks #999999 out of 387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fluicell AB has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #999999 out of 387 companies for EV-to-EBIT. This places Fluicell AB in the lower half of its industry. The industry median EV-to-EBIT is 12.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.63, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current EV-to-EBIT is -9.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Modestly Undervalued. The stock's GF Value™ is kr33.90, compared to a current price of kr30.50 — trading 10% below its estimated fair value. The current EV-to-EBIT is -9.27. Fluicell AB's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current EV-to-EBIT is -9.27 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr30.50 is trading 10% below its estimated GF Value™ of kr33.90.
GuruFocus considers Fluicell AB to be Modestly Undervalued.
Key valuation signals for OSTO:FLUI:
EV-to-EBIT: -9.27
GF Value™: kr33.90 vs. price of kr30.50 (10% below fair value)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
54GF Score
Get the complete analysis for OSTO:FLUI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
